Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.

Clinical advances in hematology & oncology : H&O - 1 Dec 2008

Lenz Heinz-Josef, Chu Edward, Grothey Axel

Abstract excerpt

As with many malignancies, cytogenetic information has become increasingly important to the diagnosis and proper treatment of colorectal cancer. In particular, several recent studies have confirmed that KRAS is not only one of the most commonly mutated genes in colorectal cancer, but also essential to treatment decision-making. Several key studies have demonstrated that patients with mutant KRAS do not respond to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cetuximab

Share to Clinical Trials as Topic

Share to Panitumumab

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19378369

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.PMID 19378369Read ↗

KRAS inhibition in metastatic colorectal cancer: An update.Semantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

EGFR and KRAS in colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing in metastatic colorectal cancer.Semantic proximity Read ↗

New strategies for treatment of KRAS mutant metastatic colorectal cancer.Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

Kras in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.Semantic proximity Read ↗

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.Semantic proximity Read ↗

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.